Industrial Report: Glucose Monitoring Devices Market Research Snapshot 2014 - Benelux And Scandinavia

MarketResearchReports.Biz presents this most up-to-date research on "Research Report On Market Snapshot - Glucose Monitoring Devices" 2014 - Benelux And Scandinavia

“Glucose Monitoring Devices 2014 – Benelux and Scandinavia” provides quantitative analysis of the two glucose monitoring devices market segments: blood glucose meters and blood glucose test strips. The analysis includes market size data by revenue and volume over the 2006–2020 period and key company share data by revenue and volume in 2013 for the following countries: are Netherlands, Belgium, Luxembourg, Sweden, Denmark and Norway. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Download Full Report with TOC: http://www.marketresearchreports.biz/analysis-details/market-snapshot-glucose-monitoring-devices-2014-benelux-and-scandinavia

Scope

•    Information on market size for the two glucose monitoring devices market segments: blood glucose meters and blood glucose test strips
•    Annualized sales data by revenue for the 2006–2020 period and company share data by revenue for 2013
•    Annualized sales data by volume for the 2006–2020 period and company share data by volume for 2013
•    Coverage of key geographies: are Netherlands, Belgium, Luxembourg, Sweden, Denmark and Norway

Reasons to Buy

•    Derive actionable insights from value-volume relationships
•    Analyze value-volume relationships and provide direction to marketing and sales strategies
•    Develop market-entry and market-expansion strategies
•    Identify the key players best positioned to take advantage of opportunities in the European market

Visit Complete Report Here: http://www.marketresearchreports.biz/sample/sample/206656

Table of Content

1 Table of Contents 1
1.1 List of Tables 3
1.2 List of Figures 4

2 Introduction 6
2.1 GBI Research Report Guidance 6

3 Glucose Monitoring Device Definitions 7
3.1 Blood Glucose Meters 7
3.1.1 Continuous Glucose Monitoring Systems 7
3.1.2 Traditional Blood Glucose Meters 7
3.2 Blood Glucose Test Strips 7

4 Glucose Monitoring Devices Market, Benelux, Revenue, 2006–2020 8
4.1 Glucose Monitoring Devices Market, Benelux, Revenue ($m), 2006–2013 8
4.2 Glucose Monitoring Devices Market, Benelux, Revenue ($m), 2013–2020 9

5 Glucose Monitoring Devices Market, Netherlands, Revenue and Volume, 2006–2020 11
5.1 Glucose Monitoring Devices Market, Netherlands, Revenue ($m), 2006–2013 11
5.2 Glucose Monitoring Devices Market, Netherlands, Revenue ($m), 2013–2020 13
5.3 Blood Glucose Meters, Netherlands 14
5.3.1 Blood Glucose Meters Market, Netherlands, Revenue ($m), 2006–2013 14
5.3.2 Blood Glucose Meters Market, Netherlands, Revenue ($m), 2013–2020 15
5.3.3 Blood Glucose Meters Market, Netherlands, Volume (‘000), 2006–2013 16
5.3.4 Blood Glucose Meters Market, Netherlands, Volume (‘000), 2013–2020 17
5.4 Blood Glucose Test Strips, Netherlands 18
5.4.1 Blood Glucose Test Strips Market, Netherlands, Revenue ($m), 2006–2013 18
5.4.2 Blood Glucose Test Strips Market, Netherlands, Revenue ($m), 2013–2020 19
5.4.3 Blood Glucose Test Strips Market, Netherlands, Volume (million), 2006–2013 20
5.4.4 Blood Glucose Test Strips Market, Netherlands, Volume (million), 2013–2020 21
5.5 Glucose Monitoring Devices Market, Netherlands, Key Company Share by Revenue (%), 2013 22
5.6 Glucose Monitoring Devices Market, Netherlands, Key Company Share by Volume (%), 2013 23

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis/206656 

6 Glucose Monitoring Devices Market, Belgium, Revenue and Volume, 2006–2020 24
6.1 Glucose Monitoring Devices Market, Belgium, Revenue ($m), 2006–2013 24
6.2 Glucose Monitoring Devices Market, Belgium, Revenue ($m), 2013–2020 26
6.3 Blood Glucose Meters, Belgium 27
6.3.1 Blood Glucose Meters Market, Belgium, Revenue ($m), 2006–2013 27
6.3.2 Blood Glucose Meters Market, Belgium, Revenue ($m), 2013–2020 28
6.3.3 Blood Glucose Meters Market, Belgium, Volume (‘000), 2006–2013 29
6.3.4 Blood Glucose Meters Market, Belgium, Volume (‘000), 2013–2020 30
6.4 Blood Glucose Test Strips, Belgium 31
6.4.1 Blood Glucose Test Strips Market, Belgium, Revenue ($m), 2006–2013 31
6.4.2 Blood Glucose Test Strips Market, Belgium, Revenue ($m), 2013–2020 32
6.4.3 Blood Glucose Test Strips Market, Belgium, Volume (million), 2006–2013 33
6.4.4 Blood Glucose Test Strips Market, Belgium, Volume (million), 2013–2020 34
6.5 Glucose Monitoring Devices Market, Belgium, Key Company Share by Revenue (%), 2013 35
6.6 Glucose Monitoring Devices Market, Belgium, Key Company Share by Volume (%), 2013 36

7 Glucose Monitoring Devices Market, Luxembourg, Revenue and Volume, 2006–2020 37
7.1 Glucose Monitoring Devices Market, Luxembourg, Revenue ($m), 2006–2013 37
7.2 Glucose Monitoring Devices Market, Luxembourg, Revenue ($m), 2013–2020 38
7.3 Blood Glucose Meters, Luxembourg 39
7.3.1 Blood Glucose Meters Market, Luxembourg, Revenue ($m), 2006–2013 39
7.3.2 Blood Glucose Meters Market, Luxembourg, Revenue ($m), 2013–2020 40
7.3.3 Blood Glucose Meters Market, Luxembourg, Volume (‘000), 2006–2013 41
7.3.4 Blood Glucose Meters Market, Luxembourg, Volume (‘000), 2013–2020 42
7.4 Blood Glucose Test Strips, Luxembourg 43
7.4.1 Blood Glucose Test Strips Market, Luxembourg, Revenue ($m), 2006–2013 43
7.4.2 Blood Glucose Test Strips Market, Luxembourg, Revenue ($m), 2013–2020 44
7.4.3 Blood Glucose Test Strips Market, Luxembourg, Volume (million), 2006–2013 45
7.4.4 Blood Glucose Test Strips Market, Luxembourg, Volume (million), 2013–2020 46
7.5 Glucose Monitoring Devices Market, Luxembourg, Key Company Share by Revenue (%), 2013 47
7.6 Glucose Monitoring Devices Market, Luxembourg, Key Company Share by Volume (%), 2013 48

8 Glucose Monitoring Devices Market, Scandinavia, Revenue, 2006–2020 49
8.1 Glucose Monitoring Devices Market, Scandinavia, Revenue ($m), 2006–2013 49
8.2 Glucose Monitoring Devices Market, Scandinavia, Revenue ($m), 2013–2020 50

9 Glucose Monitoring Devices Market, Sweden, Revenue and Volume, 2006–2020 51
9.1 Glucose Monitoring Devices Market, Sweden, Revenue ($m), 2006–2013 51
9.2 Glucose Monitoring Devices Market, Sweden, Revenue ($m), 2013–2020 52
9.3 Blood Glucose Meters, Sweden 53
9.3.1 Blood Glucose Meters Market, Sweden, Revenue ($m), 2006–2013 53
9.3.2 Blood Glucose Meters Market, Sweden, Revenue ($m), 2013–2020 55
9.3.3 Blood Glucose Meters Market, Sweden, Volume (‘000), 2006–2013 56
9.3.4 Blood Glucose Meters Market, Sweden, Volume (‘000), 2013–2020 57
9.4 Blood Glucose Test Strips, Sweden 58
9.4.1 Blood Glucose Test Strips Market, Sweden, Revenue ($m), 2006–2013 58
9.4.2 Blood Glucose Test Strips Market, Sweden, Revenue ($m), 2013–2020 59
9.4.3 Blood Glucose Test Strips Market, Sweden, Volume (million), 2006–2013 60
9.4.4 Blood Glucose Test Strips Market, Sweden, Volume (million), 2013–2020 61
9.5 Glucose Monitoring Devices Market, Sweden, Key Company Share by Revenue (%), 2013 62
9.6 Glucose Monitoring Devices Market, Sweden, Key Company Share by Volume (%), 2013 63

10 Glucose Monitoring Devices Market, Denmark, Revenue and Volume, 2006–2020 64
10.1 Glucose Monitoring Devices Market, Denmark, Revenue ($m), 2006–2013 64
10.2 Glucose Monitoring Devices Market, Denmark, Revenue ($m), 2013–2020 65
10.3 Blood Glucose Meters, Denmark 66
10.3.1 Blood Glucose Meters Market, Denmark, Revenue ($m), 2006–2013 66
10.3.2 Blood Glucose Meters Market, Denmark, Revenue ($m), 2013–2020 68
10.3.3 Blood Glucose Meters Market, Denmark, Volume (‘000), 2006–2013 69
10.3.4 Blood Glucose Meters Market, Denmark, Volume (‘000), 2013–2020 70
10.4 Blood Glucose Test Strips, Denmark 71
10.4.1 Blood Glucose Test Strips Market, Denmark, Revenue ($m), 2006–2013 71
10.4.2 Blood Glucose Test Strips Market, Denmark, Revenue ($m), 2013–2020 72
10.4.3 Blood Glucose Test Strips Market, Denmark, Volume (million), 2006–2013 73
10.4.4 Blood Glucose Test Strips Market, Denmark, Volume (million), 2013–2020 74
10.5 Glucose Monitoring Devices Market, Denmark, Key Company Share by Revenue (%), 2013 75
10.6 Glucose Monitoring Devices Market, Denmark, Key Company Share by Volume (%), 2013 76

11 Glucose Monitoring Devices Market, Norway, Revenue and Volume, 2006–2020 76
11.1 Glucose Monitoring Devices Market, Norway, Revenue ($m), 2006–2013 76
11.2 Glucose Monitoring Devices Market, Norway, Revenue ($m), 2013–2020 78
11.3 Blood Glucose Meters, Norway 79
11.3.1 Blood Glucose Meters Market, Norway, Revenue ($m), 2006–2013 79
11.3.2 Blood Glucose Meters Market, Norway, Revenue ($m), 2013–2020 81
11.3.3 Blood Glucose Meters Market, Norway, Volume (‘000), 2006–2013 82
11.3.4 Blood Glucose Meters Market, Norway, Volume (‘000), 2013–2020 83
11.4 Blood Glucose Test Strips, Norway 84
11.4.1 Blood Glucose Test Strips Market, Norway, Revenue ($m), 2006–2013 84
11.4.2 Blood Glucose Test Strips Market, Norway, Revenue ($m), 2013–2020 85
11.4.3 Blood Glucose Test Strips Market, Norway, Volume (million), 2006–2013 86
11.4.4 Blood Glucose Test Strips Market, Norway, Volume (million), 2013–2020 87
11.5 Glucose Monitoring Devices Market, Norway, Key Company Share by Revenue (%), 2013 88
11.6 Glucose Monitoring Devices Market, Norway, Key Company Share by Volume (%), 2013 89


About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. 

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/

New Research: Glioblastoma Multiforme Therapeutics In Major Developed Market Overview 2020

MarketResearchReports.Biz presents this most up-to-date research on "Research Report On Glioblastoma Multiforme Therapeutics In Major Developed Markets" To 2019 - Growth To Hinge On The Success Of Personalized Vaccine Following Early Approval In Germany

Business intelligence provider, has released its latest research report: “Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany”. Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck’s Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche’s Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment. During the 2012–2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m.

Download Full Report with TOC: http://www.marketresearchreports.biz/analysis-details/glioblastoma-multiforme-therapeutics-in-major-developed-markets-to-2019-growth-to-hinge-on-the-success-of-personalized-vaccine-following-early-approval-in-germany

The market entry of Northwest Biotherapeutics’ DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials. The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline.

Scope

•    A brief introduction to GBM, including the disease pathogenesis, risk factors and diagnosis
•    In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy
•    A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target
•    Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate
•    Multi-scenario forecast data for the GBM market to 2019, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain
•    Discussion of the drivers of and barriers to market growth
•    Discussion of the licensing and co-development deals landscape in GBM

Visit Complete Report Here: http://www.marketresearchreports.biz/sample/sample/206655

Reasons to Buy
•    Understand the different levels of GBM therapies for newly diagnosed and recurrent GBM
•    Understand the vast scope of the pipeline and determine which molecule types and mechanisms of action are prominent
•    Observe the trends in clinical trial duration and size by clinical Phase and molecule type, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for GBM therapeutics
•    Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the GBM therapeutics market

Table of Content

1 Table of Contents 1
1.1 List of Tables 3
1.2 List of Figures 4

2 Executive Summary 5
2.1 Significant Market Growth Driven by Personalized Vaccine DCVax-L 5
2.2 Challenging Clinical Trial Landscape Poses Barrier to Market Entrants 5
2.3 Significant Presence of Targeted Therapies from Phase II to Phase III of the Pipeline 5

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis/206655 

3 Introduction 5
3.1 Disease Introduction 6
3.2 Classification of Brain Tumors 6
3.3 Tumor Grading 9
3.4 Subtypes of Glioblastoma Multiforme 10
3.5 Etiology 10
3.6 Pathophysiology 11
3.6.1 Loss of Heterozygosity of Chromosome 10 12
3.6.2 Epidermal Growth Factor Receptor Amplification 12
3.6.3 Phosphatase and Tensin Homolog Mutation 12
3.6.4 Loss of p53 Function 13
3.6.5 p16INK4a Alteration and Loss of Normal Retinoblastoma 1 Function 13
3.6.6 Isocitrate Dehydrogenase 1 or Isocitrate Dehydrogenase 2 Mutation 13
3.7 Symptoms 14
3.8 Diagnosis 15
3.9 Prognosis 16
3.10 Epidemiology 17
3.11 Treatment options 18
3.11.1 Surgery 18
3.11.2 Radiotherapy 18
3.11.3 Chemotherapy 19
3.11.4 Targeted Therapy 20
3.11.5 Drugs for symptoms relief 20
3.11.6 Other alternative therapies 20
3.12 Treatment algorithm 21
3.13 GBI Research Report Guidance 24


About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. 

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/

New Report: Anti-Hypertensive Therapeutics In Major Developed Recent Market 2020

MarketResearchReports.Biz presents this most up-to-date research on "Research Report On Anti-Hypertensive Therapeutics In Major Developed Markets" To 2020 - Increased Uptake Of Combination Therapies To Offset Effects Of Key Patent Expiries

Business intelligence provider, has released its latest research: ‘Anti-Hypertensive Therapeutics in Major Developed Markets to 2020 – Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries ’, which provides in-depth analysis of hypertension therapeutics market within the eight major geographies of the US, the top five European countries (the UK, France, Germany, Spain and Italy), Japan and Canada.

Download Full Report with TOC: http://www.marketresearchreports.biz/analysis-details/anti-hypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries

The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017.

Visit Complete Report Here: http://www.marketresearchreports.biz/sample/sample/206657

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the hypertension in the major developed markets.

The report includes:

•    Disease overview, as well as treatment algorithms and treatment use patterns
•    Market size and forecast for the hypertension market from 2013–2020
•    Major marketed products for hypertension along with a heat map of product performance
•    In-depth pipeline analysis for global pipeline in hypertension along with clinical trial failure rate analysis
•    Key drivers and restraints that have had and are expected to have a significant impact upon the market
•    Key licensing and co-development agreements that could have impact on growth trends

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis/206657

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

•    Align your product portfolio to the markets with high growth potential
•    Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
•    Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the hypertension therapeutics market
•    Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
•    Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.


About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. 

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/

New Study: Breast Cancer Therapeutics In Major Developed Top Rated Market 2020

MarketResearchReports.Biz presents this most up-to-date research on "Research Report On Breast Cancer Therapeutics In Major Developed Markets" To 2020 - Approval Of Novel Therapies To Support Continued Dominance Of HER2 Targeted Drugs

Business intelligence provider, has released its latest research: ‘Breast Cancer Therapeutics in Major Developed Markets to 2020 – Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs ’, which provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The breast cancer therapeutics market in the eight major markets – The US, The UK, France, Germany, Spain, Italy, Japan and Canada – was worth $9.2 billion in 2013, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.1% to $13.1 billion by 2020. The US had the largest market in 2013, valued at $5.5 billion, equivalent to a global share of 59%, followed by Japan with $871.5m or 9.4% and Italy with $668.5m or 7.2%. Canada had the lowest market share and value of the leading eight at 2.9% and $268.4m, but is expected to witness rapid growth over the forecast period with a CAGR of 6.7%. This will only be surpassed by Japan, which is expected to witness growth at a CAGR of 6.9%.

Download Full Report with TOC: http://www.marketresearchreports.biz/analysis-details/breast-cancer-therapeutics-in-major-developed-markets-to-2020-approval-of-novel-therapies-to-support-continued-dominance-of-her2-targeted-drugs

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer in the major developed markets.

The report includes:

•    Disease overview, as well as treatment algorithms and treatment usage patterns
•    Market size and forecast for the breast cancer market from 2012 to 2019
•    Major marketed products for breast cancer along with a heat map of product performance
•    In-depth pipeline analysis for global pipeline in breast cancer along with clinical trial failure rate analysis
•    Key drivers and restraints that have had and are expected to have a significant impact upon the market
•    Key licensing and co-development agreements that could have impact on growth trends

Visit Complete Report Here: http://www.marketresearchreports.biz/sample/sample/206658

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

•    Align your product portfolio to the markets with high growth potential
•    Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
•    Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer therapeutics market
•    Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
•    Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis/206658

Table of Content

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Introduction 9
2.1 Breast Cancer 9
2.2 Symptoms 9
2.3 Epidemiology 10
2.4 Pathophysiology 11
2.5 Diagnosis 11
2.6 Prognosis and Disease Staging 12
2.6.1 Classification 13
2.7 Treatment Options 14
2.7.1 Surgery and Radiation Therapy 14
2.7.2 Chemotherapy 14
2.7.3 Hormonal Therapies 15
2.7.4 Targeted Therapies 15
2.7.5 Resistance to Pharmacological Therapies 16
2.7.6 Treatment Guidelines 17
2.7.7 Measuring the Effectiveness of Treatment 18

3 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Marketed Products 20
3.1 Key Marketed Products 20
3.1.1 Herceptin 20
3.1.2 Halaven 21
3.1.3 Avastin 22
3.1.4 Gemzar 23
3.1.5 Taxotere 23
3.1.6 Tykerb 24
3.1.7 Femara 25
3.1.8 Aromasin 26
3.1.9 Zoladex 26
3.1.10 Arimidex 27
3.2 Heat Map for Marketed Products 27


About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. 

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/